Mesenchymal Cell News 11.11 March 26, 2019 | |
| |
TOP STORYHow ‘Sleeper Cell’ Cancer Stem Cells Are Maintained in Chronic Myelogenous Leukemia Ravi Bhatia, MD, and colleagues described how niche-specific expression of a particular chemokine by a particular type of bone marrow cell controlled quiescence of these treatment-resistant leukemic stem cells. The chemokine was CXCL12, and the particular bone marrow cells expressing it were mesenchymal stromal cells. [Press release from University of Alabama at Birmingham discussing online prepublication in Cell Stem Cell] Press Release | Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)IN VITROInvestigators carried out physical and direct variant to gene mapping in human mesenchymal progenitor cell-derived osteoblasts employing a massively parallel, high resolution Capture C based method in order to simultaneously characterize the genome-wide interactions of all human promoters. [Nat Commun] Full Article | Press Release Microscopy showed that gelatin microspheres could be successfully incorporated within human periosteum derived cell micromasses without interfering with the formation of the structure, while biochemical analysis and histology demonstrated increasing DNA content at week two and accumulation of glycosaminoglycan and collagen at weeks two and four. [Acta Biomater] Abstract | Graphical Abstract To explore differences between native MSCs (nMSCs) and iPSC-derived MSCs (iMSCs), scientists developed isogeneic lines from Wharton’s jelly from the umbilical cords of two donors under xeno-free conditions. They demonstrated that although both differentiation protocols yielded iMSCs similar to their parental nMSCs, there were substantial differences. [Cell Death Dis] Full Article Epigenetic Alterations in Mesenchymal Stem Cells by Osteosarcoma-Derived Extracellular Vesicles MSCs and pre-osteoblasts were treated with osteosarcoma (OS)-extracellular vesicles (EVs) at different time points, and the epigenetic signature of OS-EVs was assessed by methylation analysis of LINE-1 (long interspersed element) and tumor suppressor genes. [Epigenetics] Full Article Real-time cell analysis and CCK8 were used to screen the best concentration of tetrahedral DNA nanostructures (TDN) for periodontal ligament stem cells (PDLSCs). Cell proliferation and osteogenic differentiation were assessed after PDLSCs were treated with TDN. [Cell Prolif] Full Article Researchers used lentiviral constructs bearing mutations R527C and R471C and explored its influence on proosteogenic phenotype expression and Notch pathway activity in four types of human cells: umbilical vein endothelial cells, cardiac mesenchymal cells, aortic smooth muscle cells, and aortic valve interstitial cells. [Cells] Full Article | Graphical Abstract IN VIVORequirement for YAP1 Signaling in Myxoid Liposarcoma Mechanistically, FUS-DDIT3 promoted YAP1 expression, nuclear localization, and transcriptional activity and physically associated with YAP1 in the nucleus of myxoid liposarcoma (MLS) cells. Pharmacologic inhibition of YAP1 activity impaired the growth of MLS cells in vitro and in vivo. [EMBO Mol Med] Full Article | Graphical Abstract Sustained released H1 effectively promoted proliferation and osteoblastic differentiation of human induced pluripotent stem cells-derived MSCs. Moreover, after eight weeks implantation in mice, this silk fibroin (SF)-H1/poly(l-lactic acid-co-ε-caprolactone) (PLCL)-hydroxyapatite composite induced bone tissue formation significantly faster than SF/PLCL as indicated by μ cysteine knot. [J Control Release] Abstract The authors developed single cell-derived clonal expansion following mesenchymal progenitor cell (MPC) derivation from somatic cell nuclear transfer-derived (SCNT)-human pluripotent stem cells (hPSCs) to offer a pure population and a higher biological activity. Additionally, they investigated the therapeutic effects of SCNT-hPSC-MPCs in model mice of Asherman’s syndrome, which is characterized by synechiae or fibrosis with endometrial injury. [Cell Prolif] Abstract Micro-CT of implanted tissues in nude mice confirmed that Distal-homeobox (Dlx) 2 overexpression in bone marrow stromal cells promoted bone formation in vivo. Dlx2 overexpression had little impact on the expression level of the pivotal osteogenic transcription factors Runx2, Dlx5, Msx2, and Osterix, but led to upregulation of Alp and Osteocalcin, both of which play critical roles in promoting osteoblast maturation. [Int J Oral Sci] Full Article Subscribe to one of our other 19 science newsletters such as ESC & iPSC News & Cell Therapy News. | |
| |
REVIEWSSynchrotron Radiation Techniques Boost the Research in Bone Tissue Engineering The authors present an overview of X-ray synchrotron radiation techniques and provide a general outlook of their applications on bone tissue engineering, with a focus on their group’s work. [Acta Biomater] Abstract Current Understanding of the Immunosuppressive Properties of Mesenchymal Stromal Cells Investigators shed light on current knowledge regarding the mechanisms by which MSCs exert immunosuppressive effects both in vitro and in vivo, focusing on the receptors expressed by MSCs, the correlation between soluble factors secreted by MSCs and their immunosuppressive effects, and interactions between MSCs and immune cells. [J Mol Med] Abstract Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field. | |
| |
INDUSTRY NEWSBrainStorm Announces Grant of an Additional New European Patent for NurOwn® BrainStorm Cell Therapeutics Inc. announced that the European Patent Office has granted a European-wide patent titled ‘Mesenchymal Stem Cells for the Treatment of CNS Diseases.’ [BrainStorm Cell Therapeutics, Inc.] Press Release Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa Mesoblast Limited announced its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has filed to extend marketing approval of TEMCELL® HS Inj. for use in patients with epidermolysis bullosa. TEMCELL is already approved for the treatment of acute graft versus host disease, and was the first allogeneic cellular medicine to receive full regulatory approval in Japan. [Mesoblast Limited] Press Release Mesoblast Limited announced that the International Center for Health Outcomes and Innovation Research at the Icahn School of Medicine at Mount Sinai and Mesoblast have entered into a Memorandum of Understanding to conduct a confirmatory clinical trial using Mesoblast’s product candidate Revascor for reduction of gastrointestinal bleeding in end-stage heart failure patients implanted with a left ventricular assist device (LVAD). [Mesoblast Limited (GlobeNewswire, Inc.)] Press Release | |
| |
POLICY NEWSDuke University Settles Research Misconduct Lawsuit for $112.5 Million Duke University will pay $112.5 million to the US government to settle a lawsuit brought by a former employee who alleged that the university included falsified data in applications and reports for federal grants worth nearly $200 million. The university will also take several steps “to improve the quality and integrity of research conducted on campus,” including the creation of a new advisory panel that will provide recommendations to the president, the Durham, North Carolina, institution said in a statement. [ScienceInsider] Editorial Top US Institutes Still Aren’t Reporting Clinical-Trial Results on Time Many leading US universities are breaking the law by failing to make public the results of clinical trials. A report found that 25 of the 40 universities that sponsor the most trials in the United States did not post study results on a public, government register within 12 months of completion, as is required by US law. [Nature News] Editorial As Elsevier Falters, Wiley Succeeds in Open-Access Deal Making Over the last few years, Project DEAL, a consortium that represents around 700 academic institutions in Germany, has been in negotiations for nationwide licensing agreements with three of the largest scholarly publishers – Elsevier, Springer Nature, and Wiley. [The Scientist] Editorial
| |
EVENTSNEW Gordon Research Conference: Lung Development, Injury and Repair 2019 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellowship – Molecular Oncology (Max Delbrück Center for Molecular Medicine) Junior Professorship – Translational Pediatric Sarcoma Research (German Research Center) Associate Professor – Department of Endocrinology (University of Southern Denmark) Assistant Professor – Medical Biotechnology (Aarhus University) Cell Biologist – MSCs & Liver Disease (Hepatx Corporation) Faculty Position – Bioengineering (University of Pittsburgh) Assistant Professor – Biomedical Engineering (Binghamton University) Assistant Professor – Sarcoma or Skeletal Related Malignancies (University of California at Davis) Assistant Professor – Department of Biological Sciences (Rutgers University Newark) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|